Hunan Jingfeng Pharmaceutical Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2020
April 29, 2021 at 04:43 pm
Share
Hunan Jingfeng Pharmaceutical Co.,Ltd. announced earnings results for the full year ended December 31, 2020. For the full year, the company announced sales was CNY 877.918 million compared to CNY 1,344.029 million a year ago. Operating loss was CNY 1,015.953 million compared to CNY 908.394 million a year ago. Net loss was CNY 969.922 million compared to CNY 882.806 million a year ago. Basic loss per share from continuing operations was CNY 1.1 compared to CNY 1 a year ago.
Hunan Jingfeng Pharmaceutical Co.,Ltd., formerly Hunan Tianyi Science and Technology Co., Ltd, is a China-based company principally engaged in the research, development, manufacture and sale of chemical drugs, biochemical drugs and traditional Chinese patent drugs. The Company's main products includes cardio and cerebrovascular drugs, antihypertensive and hypolipidemic drugs, orthopedic drugs, anti-tumor products, endocrine drugs, digestive system drugs, antiviral drugs and anti-infective drugs, among others. The Company is also involved in commodity import and export trading, business management and consulting, as well as medical technology consulting business. The Company distributes its products in the domestic market.
HUNAN JINGFENG PHARMACEUTICAL CO.,LTD. 
